润都股份：苯磺顺阿曲库铵获化学原料药上市申请批准

Core Viewpoint - The company, Rundu Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of its drug, Benzylsuccinate Atracurium, which is intended for use in surgical procedures and intensive care treatments [1] Group 1: Product Approval - Rundu Pharmaceutical's subsidiary, Rundu Pharmaceutical (Jingmen) Co., Ltd., has been granted a marketing approval notice for Benzylsuccinate Atracurium [1] - The drug is suitable for adults and children aged one month and older, specifically for surgical operations and other therapeutic procedures [1] - It can be used as an adjunct to general anesthesia or for sedation in the ICU to facilitate tracheal intubation and mechanical ventilation [1]